Pulmonx Corporation reported a significant increase in revenue for the second quarter of 2021, with worldwide revenue reaching $12.2 million, a 232% increase compared to the same period last year. The company's gross margin also improved significantly, reaching 74% compared to 28% in the second quarter of 2020. They are updating its full year 2021 revenue guidance to be in the range of $49 to $51 million.
Worldwide revenue increased by 232% to $12.2 million in the second quarter of 2021 compared to the same period last year.
Gross margin reached 74% in the second quarter of 2021, a significant increase from 28% in the same period last year.
20 new U.S. Zephyr® Valve treating centers were added, bringing the total to 180.
A software upgrade for Chartis® was launched to enable simpler and faster patient assessment of collateral ventilation.
Pulmonx is updating its full year 2021 revenue guidance to be in the range of $49 to $51 million. Pulmonx continues to expect total operating expenses for the full year 2021 to remain in the range of $85 to $90 million inclusive of stock-based compensation.
Analyze how earnings announcements historically affect stock price performance